Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 1/2 Clinical Trial for OPA-6566 in Patients with Open-angle Glaucoma or Ocular Hypertension
SEATTLE & TOKYO--(BUSINESS WIRE)--Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced the initiation of a Phase 1/2 clinical trial for OPA-6566. OPA-6566, an adenosine A2a receptor agonist, is being developed as an ophthalmic solution to reduce intraocular pressure in open-angle glaucoma (OAG) or ocular hypertension patients. OPA-6566 was discovered by Otsuka. The compound offers
